Levoketoconazole in the treatment of patients with endogenous Cushing ’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)
ConclusionsLevoketoconazole reversibly normalized urinary cortisol in patients with Cushing ’s syndrome. No new risks of levoketoconazole treatment were identified.
Source: Pituitary - Category: Endocrinology Source Type: research
More News: Addison's Disease | Adrenal Insufficiency | Endocrinology | Liver | Study | Urology & Nephrology